​

Cidara Therapeutics (CDTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CDTX Stock Forecast

Cidara Therapeutics (CDTX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $48.00, with a high of $50.00 and a low of $46.00. This represents a 97.86% increase from the last price of $24.26.

- $10 $20 $30 $40 $50 High: $50 Avg: $48 Low: $46 Last Closed Price: $24.26

CDTX Stock Rating

Cidara Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 1 Strong Buy (9.09%), 10 Buy (90.91%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 10 1 Strong Sell Sell Hold Buy Strong Buy

CDTX Price Target Upside V Benchmarks

TypeNameUpside
StockCidara Therapeutics97.86%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts113
Avg Price Target$50.00$50.00$36.00
Last Closing Price$24.26$24.26$24.26
Upside/Downside106.10%106.10%48.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2532---5
May, 2542---6
Apr, 2542---6
Mar, 2532---5
Feb, 2532---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 16, 2025Seamus FernandezGuggenheim$50.00$25.5096.08%106.10%
Mar 12, 2025Roy BuchananJMP Securities$46.00$21.00119.05%89.61%
Aug 14, 2024Ed ArceH.C. Wainwright$12.00$6.4386.63%-50.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 23, 2025RBC CapitalOutperformOutperformhold
May 16, 2025GuggenheimBuyBuyhold
Mar 12, 2025CitigroupOutperforminitialise
Aug 14, 2024H.C. WainwrightBuyupgrade
May 12, 2022NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-35 $-28 $-21 $-14 $-7 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-34.83$-16.75$-8.53$-5.25$-26.82----
Avg Forecast$-30.90$-17.67$-8.33$-5.60$-24.17$-9.59$-9.50$-8.39$-4.60
High Forecast$-30.49$-17.43$-7.88$-5.60$-24.17$-9.59$-3.41$-3.06$-4.60
Low Forecast$-31.31$-17.90$-8.71$-5.60$-24.17$-9.59$-17.63$-17.31$-4.60
Surprise %12.72%-5.21%2.40%-6.25%10.96%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.07M$49.57M$64.29M$63.91M$1.27M----
Avg Forecast$18.53M$46.64M$64.69M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
High Forecast$18.72M$47.11M$66.96M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Low Forecast$18.35M$46.17M$61.97M$60.25M$5.03M$53.59M$132.54M$10.83M$62.41M
Surprise %-34.89%6.28%-0.62%6.07%-74.67%----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.37M$-43.91M$-29.80M$-22.93M$-170.29M----
Avg Forecast$-49.20M$-77.23M$-35.59M$-22.93M$-105.63M$-41.91M$-45.98M$-44.51M$-20.11M
High Forecast$-39.36M$-76.21M$-18.86M$-13.30M$-105.63M$-41.91M$-14.89M$-13.37M$-20.11M
Low Forecast$-59.04M$-78.24M$-52.32M$-32.57M$-105.63M$-41.91M$-77.07M$-75.65M$-20.11M
Surprise %47.10%-43.14%-16.27%-61.21%----

CDTX Forecast FAQ

Is Cidara Therapeutics stock a buy?

Cidara Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cidara Therapeutics is a favorable investment for most analysts.

What is Cidara Therapeutics's price target?

Cidara Therapeutics's price target, set by 11 Wall Street analysts, averages $48 over the next 12 months. The price target range spans from $46 at the low end to $50 at the high end, suggesting a potential 97.86% change from the previous closing price of $24.26.

How does Cidara Therapeutics stock forecast compare to its benchmarks?

Cidara Therapeutics's stock forecast shows a 97.86% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Cidara Therapeutics over the past three months?

  • June 2025: 60.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cidara Therapeutics’s EPS forecast?

Cidara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-9.59, marking a -64.24% decrease from the reported $-26.82 in 2024. Estimates for the following years are $-9.5 in 2026, $-8.39 in 2027, and $-4.6 in 2028.

What is Cidara Therapeutics’s revenue forecast?

Cidara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $53.59M, reflecting a 4102.86% increase from the reported $1.28M in 2024. The forecast for 2026 is $132.54M, followed by $10.83M for 2027, and $62.41M for 2028.

What is Cidara Therapeutics’s net income forecast?

Cidara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-41.907M, representing a -75.39% decrease from the reported $-170M in 2024. Projections indicate $-45.978M in 2026, $-44.51M in 2027, and $-20.108M in 2028.